Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06328686 · ClinicalTrials.gov registry record · Early Phase 1

Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases

A Early Phase 1 study of Metastatic Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Brain, sponsored by Emory University.

Recruiting
Registry status
Early Phase 1
Development phase
10
Enrollment target
1
Study location

NCT06328686 is a Early Phase 1 study of Metastatic Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Brain that is actively recruiting participants, run by Emory University. The registered enrollment target is 10 participants, below the 206-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06328686, a Early Phase 1 study of Metastatic Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Brain, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
Early Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This early phase I trial evaluates different administration techniques (oral or intravenous) for arginine and tests the safety of giving arginine with whole brain radiation therapy in patients who have cancer that has spread from where it first started (primary site) to the brain (brain metastases). Arginine is an essential amino acid. Amino acids are the molecules that join together to form proteins in the body. Arginine supplementation has been shown to improve how brain metastases respond to radiation therapy. The optimal dosing of arginine for this purpose has not been determined. This study measures the level of arginine in the blood with oral and intravenous dosing at specific time intervals before and after drug administration to determine the best dosing strategy.

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • DIETARY_SUPPLEMENT Arginine
  • PROCEDURE Spectroscopy

Study Locations (1)

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2024-09-05
Est. Completion 2027-12-31
Phase Early Phase 1

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT06328686

The ClinicalTrials.gov registry entry for NCT06328686 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (95% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06328686 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT06328686 about?

NCT06328686 is a clinical study titled "Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases". This early phase I trial evaluates different administration techniques (oral or intravenous) for arginine and tests the safety of giving arginine with whole brain radiation therapy in patients who have cancer that has spread from where it first started (primary site) to the brain (brain metastases)....

What is the current status of trial NCT06328686?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2024-09-05. Estimated completion is 2027-12-31.

What conditions does trial NCT06328686 study?

This clinical trial studies the following conditions: Metastatic Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain.

What interventions are being tested in trial NCT06328686?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Arginine (DIETARY_SUPPLEMENT), Spectroscopy (PROCEDURE).

Who is sponsoring clinical trial NCT06328686?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06328686 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.